Treatment of Patients in the Vulnerable Phase (at Discharge or Early after Discharge)

Yuri M. Lopatin, Giuseppe MC Rosano

Abstract


The clinical course of heart failure includes a period in which the patient is at increased risk of death or rehospitalisation for HF. This period is termed the “vulnerable phase” and occurs during the peri-acute HF phase, due to microenvironmental changes in the cardiovascular system. Typically, the vulnerability phase starts from the onset of an acute HF event leading to admission, continues through a peri-discharge period and lasts up to 6 months after discharge.These poor post-discharge outcomes also represent a significant socioeconomic burden. This articles reviews treatments that are beneficial in this important phase.

Full Text:

444

References


Gheorghiade, M., P. S. Pang, A. P. Ambrosy, G. Lan, P. Schmidt, G. Filippatos, M. Konstam, K. Swedberg, T. Cook, B. Traver, A. Maggioni, J. Burnett, L. Grinfeld, J. Udelson and F. Zannad (2012). A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev 17(3): 485-509.

Yilmaz, M. B. and A. Mebazaa (2015). Definition and characteristics of the vulnerable phase in heart failure. Medicographia 37(2): 1-5.

Follath, F., M. B. Yilmaz, J. F. Delgado, J. T. Parissis, R. Porcher, E. Gayat, N. Burrows, A. McLean, F. Vilas- Boas and A. Mebazaa (2011). Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM- HF). Intensive Care Med 37(4): 619–626.

Farmakis, D., G. Filippatos, J. Parissis and J. Lekakis (2015). The social and economic burden of hospitalization for heart failure. Medicographia 37(2): 135–138.

Gheorghiade, M., M. Vaduganathan, G. C. Fonarow and R. O. Bonow (2013). Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol 61(4): 391–403.

Metra, M., V. Carubelli, I. Castrini, A. Ravera, E. Sciatti and C. Lombardi (2015). Postdischarge outcomes of patients hospitalized for heart failure. Medicographia 37(2): 139–143.

Zamorano, J. L. and V. C. Lozano (2015). Impact of quality improvement initiatives in patients hospitalized for heart failure. Medicographia 37(2): 163–169.

Ponikowski, P. and E. A. Jankowska (2015). Treatment optimization in heart failure patients from admission to discharge. Medicographia 37(2): 149–154.

Ponikowski, P., A. A. Voors, S. D. Anker, H. Bueno, J. Cleland, A. Coats, V. Falk, J. R. Gonzalez- Juanatey, V. Harjola, E. Jankowska, M. Jessup, C. Linde, P. Nihoyannopoulos, J. T. Parissis, B. Pieske, J. Riley, G. M. C. Rosano, L. Ruilope, F. Ruschitzka, F. H. Rutten and P. van der Meer (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal.

Gheorghiade, M., F. Follath, P. Ponikowski, J. H. Barsuk, J. E. Blair, J. G. Cleland, K. Dickstein, M. H. Drazner, G. C. Fonarow, T. Jaarsma, G. Jondeau, J. L. Sendon, A. Mebazaa, M. Metra, M. Nieminen, P. S. Pang, P. Seferovic, L. W. Stevenson, D. J. van Veldhuisen, F. Zannad, S. D. Anker, A. Rhodes, J. J. McMurray, G. Filippatos, C. European Society of and M. European Society of Intensive Care (2010). Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 12(5): 423–433.

Bohm, M., A. Link, D. Cai, M. S. Nieminen, G. S. Filippatos, R. Salem, A. Cohen Solal, B. Huang, R. J. Padley, M. Kivikko and A. Mebazaa (2011). Beneficial association of beta- blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial. Crit Care Med 39(5): 940–944.

Chun, S., J. V. Tu, H. C. Wijeysundera, P. C. Austin, X. Wang, D. Levy and D. S. Lee (2012). Lifetime analysis of hospitalizations and survival of patients newly admitted with heart failure. Circ Heart Fail 5(4): 414–421.

Bocchi, E. A., D. A. Brito, O. Chioncel, A. Fong, M. Hülsmann, E. A. Jankowska, M. Loutfi, A. Lupi, Y. F. M. Nosir, E. B. Reyes, S. N. Tereschenko, M. B. Yilmaz and B. Yoo (2015). Can biomarkers guide the assessment and management of heart failure patients after discharge from hospitals? Medicographia 37(2): 171–184.

Mebazaa, A., M. B. Yilmaz, P. Levy, P. Ponikowski, W. F. Peacock, S. Laribi, A. D. Ristic, E. Lambrinou, J. Masip, J. P. Riley, T. McDonagh, C. Mueller, C. deFilippi, V. P. Harjola, H. Thiele, M. F. Piepoli, M. Metra, A. Maggioni, J. J. McMurray, K. Dickstein, K. Damman, P. M. Seferovic, F. Ruschitzka, A. F. Leite- Moreira, A. Bellou, S. D. Anker and G. Filippatos (2015). Recommendations on pre- hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine – short version. Eur Heart J 36(30): 1958–1966.

Böhm, M. (2015). Challenges in predicting heart failure readmission: focus on heart rate. Medicographia 37(2): 197–201.

Bohm, M., K. Swedberg, M. Komajda, J. S. Borer, I. Ford, A. Dubost- Brama, G. Lerebours, L. Tavazzi and S. Investigators (2010). Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo- controlled trial. Lancet 376(9744): 886–894.

Elyubaeva, I. (2015). Procoralan: new opportunities for vulnerable heart failure patients. Medicographia 37(2): 185–192.

Hidalgo, F. J., M. Anguita, J. C. Castillo, S. Rodriguez, L. Pardo, E. Duran, J. J. Sanchez, C. Ferreiro, M. Pan, D. Mesa, M. Delgado and M. Ruiz (2016). Effect of early treatment with ivabradine combined with beta- blockers versus beta- blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC- AHF): A randomised study. Int J Cardiol 217: 7–11.

Cowie, M. R. (2015). Postdischarge assessment and management of patients with heart failure. Medicographia 37(2): 155–162.

Jourdain, P. (2015). Therapeutic education: which tool for whom? Medicographia 37(2): 193–196.

Zugck, C. (2015). Telemonitoring in heart failure management: what is needed to make it fit for routine use? Medicographia 37(2): 202–207.

Komajda, M. (2015). Hospitalization for heart failure: can we prevent it? Can we predict it? Medicographia 37(2): 119–124.

Inglis, S. C., R. A. Clark, F. A. McAlister, S. Stewart and J. G. Cleland (2011). Which components of heart failure programmes are effective? A systematic review and meta- analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: Abridged Cochrane Review. Eur J Heart Fail 13(9): 1028–1040.

López- Sendón, J. and N. Montoro (2015). The changing landscape of heart failure outcomes. Medicographia 37(2): 125–134.

Shewan L.G., Coats A.J.S., Henein M. Requirements for Ethical Publishing in Biomedical Journals. International Cardiovascular Forum Journal. 2015;2:2. http://dx.doi.org/10.17987/icfj.v2i1.4




DOI: https://doi.org/10.17987/icfj.v10i0.444


Copyright (c) 2017 The Authors

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.